Background: Posterior reversible encephalopathy syndrome (PRES) is a rare but serious complication after allogeneic hematopoietic stem cell transplantation (alloHSCT). Among others, calcineurin inhibitors (CNI) for prophylaxis of graft-versus-host disease (GvHD) may promote the development of PRES, but the pathomechanism is still controversial. Discontinuation of CNI facilitates remission of symptoms but might contribute to the unfavorable prognosis of PRES due to an elevated incidence of GvHD. Methods: This is a case series of 7 patients with PRES from a retrospective analysis of 146 consecutive patients who received alloHSCT for hematologic malignancies. Results: At the onset of PRES, all patients presented a systemic infection, while no influence was seen for underlying disease, conditioning regimen, donor type, or GvHD. Discontinuation of CNI and control of the blood pressure reversed neurological symptoms in 6 patients, while 1 patient died from septic multiorgan failure. After bridging with prednisolone and/or mycophenolic acid, replacement of CNI by the mammalian target of rapamycin (mTOR) inhibitor everolimus effectively prevented severe GvHD without recurrence of PRES. Conclusions: A systemic infection/inflammation may be an important cause of PRES. Prophylaxis of GvHD by the mTOR inhibitor everolimus in case of PRES after alloHSCT demonstrated promising results but needs to be validated in larger cohorts.

Keywords:
Allogeneic stem cell transplantation, Everolimus, Graft-versus-host prophylaxis, Posterior reversible encephalopathy syndrome
1.
Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM: Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002;100:406-414.
2.
Gratwohl A, Brand R, Apperley J, Biezen AV, Bandini G, Devergie A, Schattenberg A, Frassoni F, Guglielmi C, Iacobelli S, Michallet M, Kolb HJ, Ruutu T, Niederwieser D; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation: Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002;100:3877-3886.
3.
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, Yee R, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314:729-735.
4.
Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D, Giralt S, Gajewski J, Fischer H, Fritsche H, Deisseroth AB, Cleary K, Champlin R, Besien K, Andersson B, Maher R, Fitzsimmons W: Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996;88:4383-4389.
5.
Apperley J, Masszi T: Graft-versus-host disease; in Apperley J, Carreras E, Gluckman E, Masszi T (eds): The EBMT Handbook - Haematopoietic Stem Cell Transplantation, ed 6. Genoa, European Society for Blood and Marrow Transplantation, 2012, pp 216-233.
6.
Woo M, Przepiorka D, Ippoliti C, Warkentin D, Khouri I, Fritsche H, Korbling M: Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant 1997;20:1095-1098.
7.
Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ, Straube A: Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 2003;60:842-848.
8.
Gijtenbeek JM, van den Bent MJ, Vecht CJ: Cyclosporine neurotoxicity: a review. J Neurol 1999;246:339-346.
9.
Bechstein WO: Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000;13:313-326.
10.
Eidelman BH, Abu-Elmagd K, Wilson J, Fung JJ, Alessiani M, Jain A, Takaya S, Todo SN, Tzakis A, Van Thiel D, Shannon W, Starzl TE: Neurologic complications of FK 506. Transplant Proc 1991;23:3175-3178.
11.
Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
12.
Garg RK: Posterior leukoencephalopathy syndrome. Postgrad Med J 2001;77:24-28.
13.
Lee VH, Wijdicks EF, Manno EM, Rabinstein AA: Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008;65:205-210.
14.
Wu Q, Marescaux C, Wolff V, Jeung MY, Kessler R, Lauer V, Chen Y: Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol 2010;64:169-177.
15.
Bartynski WS, Boardman JF: Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2007;28:1320-1327.
16.
Bartynski WS: Posterior reversible encephalopathy syndrome. 1. Fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008;29:1036-1042.
17.
Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA: Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010;85:427-432.
18.
Schwartz RB, Bravo SM, Klufas RA, Hsu L, Barnes PD, Robson CD, Antin JH: Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995;165:627-631.
19.
Bartynski WS, Boardman JF: Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2008;29:447-455.
20.
Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, Forman AD, Kumar AJ, Champlin R, Couriel D: Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2003;122:128-134.
21.
Siegal D, Keller A, Xu W, Bhuta S, Kim DH, Kuruvilla J, Lipton JH, Messner H, Gupta V: Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant 2007;13:1369-1379.
22.
Bartynski WS, Zeigler ZR, Shadduck RK, Lister J: Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. AJNR Am J Neuroradiol 2004;25:261-269.
23.
Bartynski WS, Zeigler ZR, Shadduck RK, Lister J: Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoietic malignancies and marrow conditions after allogeneic bone marrow transplantation. Neurocrit Care 2005;3:33-45.
24.
Kishi Y, Miyakoshi S, Kami M, Ikeda M, Katayama Y, Murashige N, Kusumi E, Yuji K, Kobayashi K, Kato D, Hamaki T, Matsumura T, Kim SW, Morinaga S, Mori S, Kanemaru M, Hayashi T, Takaue Y, Taniguchi S; Tokyo Stem Cell Transplantation Consortium: Early central nervous system complications after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant 2004;10:561-568.
25.
Barba P, Pinana JL, Valcarcel D, Querol L, Martino R, Sureda A, Briones J, Delgado J, Brunet S, Sierra J: Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009;15:1439-1446.
26.
Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ: Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:300-308.
27.
Gallardo D, Ferra C, Berlanga JJ, Banda ED, Ponce C, Salar A, Alonso E, Espannol I, Riu C, Granena A: Neurologic complications after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;18:1135-1139.
28.
Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U: Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol 2013;88:301-305.
29.
Schwartz RB: A reversible posterior leukencephalopathy syndrome (letter). N Engl J Med 1996;334:1743.
30.
Ay H, Buonanno FS, Schaefer PW, Le DA, Wang B, Gonzalez RG, Koroshetz WJ: Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 1998;51:1369-1376.
31.
Kheir JN, Lawlor MW, Ahn ES, Lehmann L, Riviello JJ, Silvera VM, McManus M, Folkerth RD: Neuropathology of a fatal case of posterior reversible encephalopathy syndrome. Pediatr Dev Pathol 2010;13:397-403.
32.
Cordelli DM, Masetti R, Bernardi B, Barcia G, Gentile V, Biagi C, Prete A, Pession A, Franzoni E: Status epilepticus as a main manifestation of posterior reversible encephalopathy syndrome after pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer 2012;58:785-790.
33.
Li Y, Jenny D, Castaldo J: Posterior reversible encephalopathy syndrome: clinicoradiological spectrum and therapeutic strategies. Hosp Pract 2012;40:202-213.
34.
Aisa Y, Mori T, Shimizu T, Tsukada Y, Kato J, Suzuki S, Suzuki N, Ikeda Y, Okamoto S: Retrospective analysis of posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation (in Japanese). Rinsho Ketsueki 2009;50:9-15.
35.
Casey SO, Sampaio RC, Michel E, Truwit CL: Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 2000;21:1199-1206.
36.
Doelken M, Lanz S, Rennert J, Alibek S, Richter G, Doerfler A: Differentiation of cytotoxic and vasogenic edema in a patient with reversible posterior leukoencephalopathy syndrome using diffusion-weighted MRI. Diagn Interv Radiol 2007;13:125-128.
37.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
38.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME: National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. 1. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956.
39.
Sayer HG, Klink A, Schenk T, Treschl A, Schilling K, Hochhaus A: Safety and efficacy of the mTOR inhibitor everolimus as early interventional replacement for calcineurin inhibitors in graft-versus-host disease (GvHD) prophylaxis after allogeneic stem cell transplantation. Blood 2010;116:960-961.
40.
Bartynski WS: Posterior reversible encephalopathy syndrome. 2. Controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 2008;29:1043-1049.
41.
Dinsdale HB: Hypertensive encephalopathy. Neurol Clin 1983;1:3-16.
42.
Ito T, Sakai T, Inagawa S, Utsu M, Bun T: MR angiography of cerebral vasospasm in preeclampsia. AJNR Am J Neuroradiol 1995;16:1344-1346.
43.
Lin JT, Wang SJ, Fuh JL, Hsiao LT, Lirng JF, Chen PM: Prolonged reversible vasospasm in cyclosporin A-induced encephalopathy. AJNR Am J Neuroradiol 2003;24:102-104.
44.
Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG: The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome: a prospective series of 67 patients. Brain 2007;130:3091-3101.
45.
Naidu K, Moodley J, Corr P, Hoffmann M: Single photon emission and cerebral computerised tomographic scan and transcranial Doppler sonographic findings in eclampsia. Br J Obstet Gynaecol 1997;104:1165-1172.
46.
Tajima Y, Isonishi K, Kashiwaba T, Tashiro K: Two similar cases of encephalopathy, possibly a reversible posterior leukoencephalopathy syndrome: serial findings of magnetic resonance imaging, SPECT and angiography. Int Med 1999;38:54-58.
47.
Bartynski WS, Zeigler Z, Spearman MP, Lin L, Shadduck RK, Lister J: Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol 2001;22:1901-1914.
48.
Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J: Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol 2006;27:2179-2190.
49.
Horbinski C, Bartynski WS, Carson-Walter E, Hamilton RL, Tan HP, Cheng S: Reversible encephalopathy after cardiac transplantation: histologic evidence of endothelial activation, T-cell specific trafficking, and vascular endothelial growth factor expression. AJNR Am J Neuroradiol 2009;30:588-590.
50.
Thompson CB, June CH, Sullivan KM, Thomas ED: Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 1984;2:1116-1120.
51.
Aisa Y, Mori T, Nakazato T, Shimizu T, Yamazaki R, Ikeda Y, Okamoto S: Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. Transplantation 2005;80:1046-1050.
52.
Zimmer WE, Hourihane JM, Wang HZ, Schriber JR: The effect of human leukocyte antigen disparity on cyclosporine neurotoxicity after allogeneic bone marrow transplantation. AJNR Am J Neuroradiol 1998;19:601-608, discussion 609-610.
53.
Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G: Cyclosporin-induced endothelial cell injury. Lab Invest 1986;55:455-462.
54.
Bloom IT, Bentley FR, Garrison RN: Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1. Surgery 1993;114:480-487, discussion 487-488.
55.
Bunchman TE, Brookshire CA: Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 1991;88:310-314.
56.
Truwit CL, Denaro CP, Lake JR, DeMarco T: MR imaging of reversible cyclosporin A-induced neurotoxicity. AJNR Am J Neuroradiol 1991;12:651-659.
57.
Dohgu S, Yamauchi A, Nakagawa S, Takata F, Kai M, Egawa T, Naito M, Tsuruo T, Sawada Y, Niwa M, Kataoka Y: Nitric oxide mediates cyclosporine-induced impairment of the blood-brain barrier in cocultures of mouse brain endothelial cells and rat astrocytes. Eur J Pharmacol 2004;505:51-59.
58.
Verbeke M, Van de Voorde J, de Ridder L, Lameire N: Functional analysis of vascular dysfunction in cyclosporin treated rats. Cardiovasc Res 1994;28:1152-1156.
59.
Antin JH, Ferrara JL: Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964-2968.
60.
Ferrara JL: Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 2000;9:299-306.
61.
Kanekiyo T, Hara J, Matsuda-Hashii Y, Fujisaki H, Tokimasa S, Sawada A, Kubota K, Shimono K, Imai K, Ozono K: Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children. Int J Hematol 2005;81:264-268.
62.
Aird WC: The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101:3765-3777.
63.
Sweany JM, Bartynski WS, Boardman JF: ‘Recurrent' posterior reversible encephalopathy syndrome: report of 3 cases - PRES can strike twice! J Comput Assist Tomogr 2007;31:148-156.
64.
Tollemar J, Ringden O, Ericzon B-G, Tyden G: Cyclosprine-associated central nervous system toxicity. N Engl J Med 1988;318:788-789.
65.
Spitzer TR: Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27:893-898.
66.
Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA: The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 2014;69:2043-2055.
67.
Chohan R, Vij R, Adkins D, Blum W, Brown R, Tomasson M, Devine S, Graubert T, Goodnough LT, DiPersio JF, Khoury H: Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. Br J Haematol 2003;123:110-113.
68.
Mori A, Tanaka J, Kobayashi S, Hashino S, Yamamoto Y, Ota S, Asaka M, Imamura M: Fatal cerebral hemorrhage associated with cyclosporin-A/FK506-related encephalopathy after allogeneic bone marrow transplantation. Ann Hematol 2000;79:588-592.
69.
Neuhaus P, Klupp J, Langrehr JM: mTOR inhibitors: an overview. Liver Transpl 2001;7:473-484.
70.
Patel JK, Kobashigawa JA: Everolimus: an immunosuppressive agent in transplantation. Expert Opin Pharmacother 2006;7:1347-1355.
71.
Vitko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y, Jappe A, Cretin N; RAD B201 Study Group: Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004;78:1532-1540.
72.
Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P; RAD B253 Study Group: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-858.
73.
Kovarik JM, Snell GI, Valentine V, Aris R, Chan CK, Schmidli H, Pirron U: Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant 2006;25:440-446.
74.
Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic SZ, Greinix H, Holler E: Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:1-17.
75.
Cutler C, Antin JH: Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. Curr Opin Hematol 2010;17:500-504.
76.
Klink A, Schilling K, Rapp K, Höffken K, Sayer HG: High overall response rate in calcineurin inhibitor-free treatment with the mTOR inhibitor everolimus in advanced extensive chronic GVHD after allogeneic stem cell transplantation. Blood 2008;112:2210.
77.
Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A, Stoehlmacher J, Schetelig J, Thiede C, Ehninger G, Bornhauser M: Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant 2009;15:101-108.
78.
Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, Morris R, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A: Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007;39:2937-2950.
79.
Lunardi N, Saraceni E, Boccagni P, Segato M, Bortolato A, Manara R, Rossi S, Ori C: Posterior reversible encephalopathy syndrome in the intensive care unit after liver transplant: a comparison of our experience with the existing literature. Minerva Anestesiol 2012;78:847-850.
80.
Alparslan M, Bora U, Huseyin K, Ayhan D, Gultekin S: Posterior reversible encephalopathy syndrome in a renal transplanted patient. Am J Case Rep 2013;14:241-244.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.